Main menu
Click categories to expand
A-Z listingplugin-autotooltip__plain plugin-autotooltip_bigA-Z listing
This is an alphabetical index of all content pages.
Other categories
Utilities
Also see
Importance Ratings
News
Legal
Donate/Sponsor
Curator's rationale
AI Policy
Twitter feed ð•
Feeds + s.e.o. etc.
rss / xml feed 
sitemap file
A-Z listing (archived)
Methocarbamol, sold under the brand names of Robaxin, Robaxin-750, Carbacot, Skelex (and others) is a prescription-only short-term medication used for pain relief in muscle spasms and for musculo-skeletal problems.
It was authorised for use in 1957, and there are currently 3 million prescriptions per year in the US alone.
It works as a centrally-acting muscle relaxant (rather than acting on the muscles themselves) but its precise pharmacological mechanism of action is unknown.
Methocarbamol is a carbamate with centrally acting muscle relaxant properties. Though the exact mechanism of action of methocarbamol was not established, it's postulated to be via a mechanism similar of carbamate, inhibition of acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system.
Source : US National Library of Medicine
Further info. Wikipedia
Ideas for new topics, and suggested additions / corrections for older ones, are always welcome.
If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !
Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.
( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)
You are currently viewing an auto-translated version of Wikenigma
Please be aware that no automatic translation engines are 100% accurate, and so the auto-translated content will very probably feature errors and omissions.
Nevertheless, Wikenigma hopes that the translated content will help to attract a wider global audience.
DOKUWIKI IMPLEMENTATION DESIGN BY UNIV.ORG.UK DECEMBER 2023